Skip to main content
Premium Trial:

Request an Annual Quote

David Daly

Foundation Medicine has appointed David Daly as chief commercial officer. He was most recently vice president of commercial operations in the Anatomic Pathology Division at Thermo Fisher Scientific. Before that, he was head of oncology, medical sciences at Life Technologies, before the company was acquired by Thermo Fisher. Daly also held several positions at Clarient, including as chief commercial officer, and before that he worked in sales and marketing at Roche Diagnostics and Abbott Laboratories.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.